Hanmi, Spectrum Look For Differentiation As Poziotinib Progresses
This article was originally published in PharmAsia News
Executive Summary
South Korea's Hanmi Pharmaceutical and its global partner Spectrum Pharmaceuticals are moving closer to the commercialization of the oral pan-HER inhibitor poziotinib in the US with the submission by the US biotech of a Phase II breast cancer protocol to the FDA as part of an IND application. But the partners are having to fine-tune their development strategy given what is a crowded sector.